Rio Tinto's half-year results for the six months ended June 30, 2026, are scheduled for release on July 29, 2026. Analysts expect continued strength in copper production from Oyu Tolgoi ramp-up, offsetting potential iron ore price volatility.
RIO stock rose +12% over the last 30 days, driven by strong copper production beats and interest in U. S.
VZ stock declined approximately -10% over the past 30 days amid analyst downgrades, profit-taking after a strong quarterly rally, and sector-wide pressures in telecommunications. Over the past quarter, the stock surged +23%, driven by robust Q4 2025 earnings beat, upbeat 2026 guidance, and strong subscriber growth including over 1 million net adds.
SYRE shares surged approximately 25% in Monday's session, with the stock rising from a previous close of $51.29 to approximately $64.11 intraday. The primary catalyst is a highly positive Phase 2 SKYLINE trial readout: SPY001 met its primary endpoint with a statistically significant 9.2-point reduction in Robart's Histopathology Index (RHI) score (p<0.0001) at Week 12 in moderate-to-severely active ulcerative colitis patients.
Shares of Revolution Medicines (RVMD) surged +37.33% in today's session, rising from a prior close of $96.43 to $132.43, with an intraday high of $135.81. The primary catalyst is a landmark Phase 3 clinical trial win: daraxonrasib nearly doubled median overall survival versus standard chemotherapy in second-line metastatic pancreatic ductal adenocarcinoma (PDAC)
LITE shares are trading down approximately 5% in Monday's session (April 13, 2026), from a prior close of $897.30 to roughly $852.44. The decline is driven primarily by broad market risk-off sentiment tied to geopolitical tensions and ongoing tariff uncertainty, with no company-specific negative catalyst.
ERAS shares declined approximately -12% intraday on Monday, April 13, 2026, pulling back sharply from a recent 52-week high of $18.20 reached on April 7. The selloff appears primarily driven by profit-taking and valuation pressure after a staggering ~1,497% rally over the past twelve months, with shares trading well above most pre-run analyst consensus targets.
Replimune Group (REPL) shares collapsed approximately 63.24% in premarket trading on Monday, April 13, 2026, falling from a Friday close of $4.76 to around $1.75. The primary catalyst is the FDA's second consecutive Complete Response Letter (CRL) issued April 10, 2026, rejecting the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.
Analysts expect Q1 2026 EPS of approximately $4.77-$4.85, up slightly from $4.65 in Q1 2025. Revenue consensus around $22.6B-$23.2B, reflecting 9.7%-4.5% year-over-year growth.
Morgan Stanley (MS) stock surged +15% over the past 30 days, driven by the launch of its low-cost Bitcoin ETF and positive analyst upgrades ahead of Q1 earnings. Over the past quarter, the stock is relatively flat at -1%, reflecting volatility from geopolitical tensions and private credit concerns offset by a strong rebound.
Goldman Sachs ( GS ) reports Q1 2026 earnings on April 13, with consensus EPS of $16.34 and revenue of $16.95 billion, signaling 16% EPS growth year-over-year. Morgan Stanley ( MS ) follows on April 15, expecting EPS of $3.02 and revenue of $19.71 billion, up 16% in EPS.
BAC stock rose approximately +11% over the past 30 days, rebounding from mid-March lows around $47 amid positive net interest income (NII, the difference between interest earned on loans and paid on deposits) guidance and analyst upgrades. Over the past quarter, the stock declined about -5%, reflecting earlier pressures from peak levels near $55 in January due to interest rate volatility and macroeconomic concerns.
ASML stock rose +9.9% over the past 30 days amid AI-driven demand for extreme ultraviolet (EUV) lithography systems, despite volatility from proposed U.S. export restrictions to China. Over the past quarter, shares gained +16.4%, supported by record bookings and strong semiconductor industry capex (capital expenditures) trends.
First Horizon ( FHN ) reports Q1 2026 earnings on April 15, with consensus EPS of $0.49 and revenue of $869 million. F.
INTU stock declined approximately -18% over the past 30 days, driven primarily by sector-wide fears of AI disruption following Anthropic's new model announcements. Over the past quarter, the stock fell around -46%, reflecting broader software sector weakness amid macroeconomic uncertainty and valuation resets.
SMH rose +10.6% over the past 30 days, driven by AI chip demand recovery and easing geopolitical tensions from Iran war ceasefire hopes. Quarterly performance shows +13.0% gain, supported by strong earnings from top holdings like NVIDIA and Taiwan Semiconductor amid sustained AI infrastructure buildout.
Salesforce (CRM) stock declined approximately -12% over the past 30 days amid sector-wide selloffs in software stocks driven by AI disruption fears. Over the past quarter, the stock fell around -35%, reflecting broader YTD losses of over 35% from early-year highs near $260.
Salesforce ( CRM ) boasts a market cap of approximately $155 billion with trailing twelve-month (TTM) revenue of $41.5 billion, dwarfing Atlassian's ( TEAM ) $15 billion market cap and $5.8 billion TTM revenue. Recent market activity has pressured both stocks amid AI disruption fears, but CRM shows resilient AI momentum via Agentforce, with $800 million annual recurring revenue (ARR), up 169% year-over-year.
APP stock declined approximately -20% over the past 30 days amid broader tech sector volatility, ongoing SEC probe concerns, and AI competition fears. Over the past quarter, the stock fell around -44%, reflecting profit-taking after strong Q4 earnings and negative sentiment from short-seller reports.
Both CRWD and MSFT have faced downward pressure in recent market activity, with year-to-date declines around 16-23% amid broader tech sector volatility. CRWD , a cybersecurity specialist, reported strong Q4 FY2026 results with 23% revenue growth to $1.31 billion and ARR of $5.25 billion, but shares dipped on AI disruption concerns.